Update From The God Himself - Dr. Takashi Tsuji

J

Joxy

Experienced Member
Reaction score
517
OrganTech got funding and partnership from Kobayashi Pharmaceutical to start clinical trials by the beginning of 2024. Not only about hair cloning, but tooth regeneration as well.

Kobayashi Pharmaceutical is planning to expand their company in regenetative medecine and AI technology in future.
 
It_is_over_for_nw7

It_is_over_for_nw7

Established Member
My Regimen
Reaction score
97
Joxy said:
OrganTech got funding and partnership from Kobayashi Pharmaceutical to start clinical trials by the beginning of 2024. Not only about hair cloning, but tooth regeneration as well.

Kobayashi Pharmaceutical is planning to expand their company in regenetative medecine and AI technology in future.
Click to expand...
Kobayashi pharmaceutical is the worst name for a pharmaceutical. Anyone who watches star trek knows about the Kobayashi maru. A simulation of a space mission designed to have you fail. Only captain kirk beat it by altering the conditions of the simulation to make it winnable.

So unless William Shatner is a key contributor, this company is doomed.
 
G

Gump

New Member
My Regimen
Reaction score
7
The fact that Tsuji couldn't get funding easily makes me suspicious he a.) hasn't solved certain key issues related to the treatment, b.) can't prove it will be as effective as everyone thinks or c.) they expect some other operational issues/contstraints going to market. A new treatment like this would be a goldmine and $500 million could be recouped relatively quickly, especially from different backers.
 
J

Joxy

Experienced Member
Reaction score
517
J

Joxy

Experienced Member
Reaction score
517
Miho Ogawa and Takashi Kondo, representative directors in OrganTech

challenger.newsweekjapan.jp

CHALLENGING INNOVATOR｜株式会社オーガンテック近藤 嵩

一見誰もが無謀と感じる挑戦こそが、世の中に新しい価値をもたらす。そしてそのチャンスは、誰にでも平等にある。今回のCHALLENGING INNOVATORは株式会社オーガンテック近藤 嵩氏です。
challenger.newsweekjapan.jp challenger.newsweekjapan.jp

Received the award in the SDGs category of the "Economist Future Award 2023" held on June 25, 2023 (Sponsor: Economist Future Award 2023 Executive Committee/Sponsor: Mainichi Shimbun Publishing Co., Ltd.)
 
S

Sanchez1234

Experienced Member
Reaction score
311
TSUJI back from the dead
FT new interview (25 oct:):
folliclethought.com

OrganTech Hair Cloning Interview 2023 - Follicle Thought

Follicle Thought is pleased to share an exclusive interview with the CEO of OrganTech as we draw closer to 2024. OrganTech Inc. Resurgence Prior to the year 2020, one researcher’s name was held synonymously with the topic of hair cloning by online hair-seeking communities – Dr. Takashi Tsuji...
folliclethought.com folliclethought.com

Summary:
- New CEO, specializes in fund raising
- “Regarding the hair regeneration business, we are preparing documents for clinical research, and we plan to transplant regenerated hair follicle primordia into humans as early as the second quarter of 2024”
- “We are planning to go public and raise funds in the stock market to further our research and development efforts. After analyzing, we believe that NASDAQ is the most suitable stock exchange for this purpose, and we have currently started preparations for the listing.”
- “continuing research to further enhance the hair growth rate and plan to sequentially perform primordia transplants into humans using new technology”

Interesting developments
 
J

Joxy

Experienced Member
Reaction score
517
OrganTech got award by Startup City for Top Biotech Startup for 2023 in APAC region.
www.startupcity.com

OrganTech | Top Biotech Startup in APAC-2023

OrganTech has been recognized as Top 10 Biotech Startups in APAC - 2023 by Startup City Magazine. OrganTech Inc., a leading Japanese biotechnology company, brings Japan's and...
www.startupcity.com www.startupcity.com
 
RolfLeeBuckler

RolfLeeBuckler

Experienced Member
My Regimen
Reaction score
984
Hairismylife said:
Hugeeeeeeee news! That means it can be commercialized in 2024? I recall that phase 2 human trial in when it can be early released.
Click to expand...
Why should be a possibility to commercialize in 2024? I mean they will do the First Trial this Year so How they Can Skip Phase II and Phase III?
 
J

Joxy

Experienced Member
Reaction score
517
RolfLeeBuckler said:
Why should be a possibility to commercialize in 2024? I mean they will do the First Trial this Year so How they Can Skip Phase II and Phase III?
Click to expand...
Because they completed Phase I safety trial. Now they will do Phase II trial for efficiency. Japan doesn’t require Phase III with new laws for regenenative medicine. If I understand correctly.
 
J

Joxy

Experienced Member
Reaction score
517
Takashi Tsuji mentioned here that they plan to put OrganTech technology in practice somewhere in 2026
globe.asahi.com

再生医療技術を活用、理研チームの「髪のタネ」量産計画は悩み解消の決定打になるか：朝日新聞GLOBE＋

古今東西、多くの人々が年齢とともに減っていく髪の毛に心を痛めてきました。かつらは借り物だし、最近はやりの自家植毛もいわば「髪の毛の引っ越し」なので、髪の総本数は増えません。いっそ「髪のタネ」の大量生産で、髪不足の一気解決を狙おう―ー。...
globe.asahi.com globe.asahi.com

I know they got permission to start clinical trials, because they confirmed the safety of technology and by the new laws in Japan they need just to evaluate efficiency in Phase II. Correct me if I am wrong?
 
J

Joxy

Experienced Member
Reaction score
517
J

Joxy

Experienced Member
Reaction score
517
CEO from OrganTech for business strategy, Takashi Kondo, was presented on biggest japanese platform for business news release:

prtimes.jp

女性研究者とファンドマネージャー　対極の2人がコラボし共同経営者に　互いの強みを生かし、世界初の器官再生技術で毛髪再生、歯科治療の事業化に挑戦

株式会社オーガンテックのプレスリリース（2024年2月15日 10時53分）女性研究者とファンドマネージャー　対極の2人がコラボし共同経営者に　互いの強みを生かし、世界初の器官再生技術で毛髪再生、歯科治療の事業化に挑戦
prtimes.jp prtimes.jp
 
J

Joxy

Experienced Member
Reaction score
517
Students from Tokyo University visited OrganTech lab and did interview with Dr. Takashi Tsuji about their technology and future plans:

note.com

11月26日　神戸理化学研究所　研修　　｜東京大学Diligent

先日の産学官共創学習ゼミでご講演をいただいた辻孝先生のご厚意で、デリゼミ生数名が神戸にある辻先生の研究室の見学をさせていただきました。 先日の辻先生のゼミの記事はこちら↓ 辻先生が立ち上げた医療ベンチャー株式会社オーガンテックのサイトこちら↓ OrganTech 日本初、世界初の臓器再生医療技術を、未来へ。 www.organ-tech.jp 私たちの団体についてはこちら↓ ①東大起業家・キャリア育成育成塾 Diligent テーマ産学官共創・キャリア育成・リーダー育成ビラを3000枚配布・ゼミ運営も開始理念産学官の知的資源を通し
note.com note.com

Quite good interview and good inside info about their current progress and future plans.
 
J

Joxy

Experienced Member
Reaction score
517
Dr. Takashi Tsuji gave presentation and lecture in front of many students about the their core technology and OrganTech future plans in next 10 years (part 2)

note.com

【自主ゼミ】産学官共創学習ゼミ第八回 2023/11/20｜東京大学Diligent

早くも第8回の折り返しに差し掛かった産学官協創学習デリゼミ。 【寄稿】Aセメに開催 東大生のためのキャリア形成ゼミ【産学官協創学習ゼミ】 - 東大新聞オンライン 産学官を見渡した学びやキャリア形成のヒントを得られる自主ゼミが、本年度Aセメスターに開講する。 www.todaishimbun.org ①東大起業家・キャリア育成育成塾 Diligent テーマ産学官共創・キャリア育成・リーダー育成ビラを3000枚配布・ゼミ運営も開始理念産学官の知的資源を通して起業家精神を現 innovation.ut-diligent2.com
note.com note.com

They believe that OrganTech technology will change science and put Japan on top of biopharma industry in future.
 
J

Joxy

Experienced Member
Reaction score
517
Dr. Takashi Tsuji interview for Tokyo University students group (part 1)

note.com

11月26日　神戸理化学研究所　研修　　｜東京大学Diligent

先日の産学官共創学習ゼミでご講演をいただいた辻孝先生のご厚意で、デリゼミ生数名が神戸にある辻先生の研究室の見学をさせていただきました。 先日の辻先生のゼミの記事はこちら↓ 辻先生が立ち上げた医療ベンチャー株式会社オーガンテックのサイトこちら↓ OrganTech 日本初、世界初の臓器再生医療技術を、未来へ。 www.organ-tech.jp 私たちの団体についてはこちら↓ ①東大起業家・キャリア育成育成塾 Diligent テーマ産学官共創・キャリア育成・リーダー育成ビラを3000枚配布・ゼミ運営も開始理念産学官の知的資源を通し
note.com note.com

Dr. Takashi Tsuji presentation in front of big students group about their core technology and future plans for OrganTech (part 2 )

note.com

【自主ゼミ】産学官共創学習ゼミ第八回 2023/11/20｜東京大学Diligent

早くも第8回の折り返しに差し掛かった産学官協創学習デリゼミ。 【寄稿】Aセメに開催 東大生のためのキャリア形成ゼミ【産学官協創学習ゼミ】 - 東大新聞オンライン 産学官を見渡した学びやキャリア形成のヒントを得られる自主ゼミが、本年度Aセメスターに開講する。 www.todaishimbun.org ①東大起業家・キャリア育成育成塾 Diligent テーマ産学官共創・キャリア育成・リーダー育成ビラを3000枚配布・ゼミ運営も開始理念産学官の知的資源を通して起業家精神を現 innovation.ut-diligent2.com
note.com note.com

Quite informative interview and positive presentation.
 
You must log in or register to reply here.
Community platform by XenForo® © 2010-2023 XenForo Ltd.
Top